Preclinical phase of Crohn’s disease – A new window of opportunity

Scientists are now uncovering the biological clues that appear years before symptoms begin. If we can pinpoint and validate these biomarkers, we could shift from reactive treatment to proactive prevention making it possible to understand what triggers the inflammatory process and what leads to a chronic and persistent immunological response. It would also make it possible to know which targets would offer the greatest benefit when treating the disease early on and potentially make preventive measures possible for those at risk of developing the disease.

INTERCEPT is at the forefront of this breakthrough in the decisive preclinical stage. Through advanced research, INTERCEPT is working to:

• Validate biomarkers that can predict disease onset.
• Identify high risk individuals in the preclinical stages before symptoms appear.
• Enable earlier, more effective interventions.

By doing so, INTERCEPT would completely revolutionise and change the prediction and treatment landscape not only of Crohn’s disease but other IBD and chronic diseases. Early becomes earlier and prevention becomes possible, changing the future for millions at risk.